Diagnostics companies and testing labs at ISLB 2026

Nov 7–9, 2026 Madrid, Spain ~700 attendees Website

21 diagnostics companies and testing labs are at ISLB 2026 — 28 presentations on the program and 11 with a booth in the exhibit hall. Most represented: Natera (3 on the program), Actorius (2 on the program), Guardant Health (2 on the program). 15 of them have their own page in this guide. As of Oct 16, 2026.

All 160 organizations at ISLB 2026 →

Showing 1–11 of 21 organizations

Organization	ISLB 2026 Attendance
Natera Austin, TX	◇Bronze Sponsor
natera.com/oncology/signatera-advanced-cancer-detection Diagnostics & testing labsBronze Sponsor Offers Signatera, a personalized ctDNA test used to assess molecular residual disease and monitor treatment, validated in multiple cancer types.	Booth Exhibiting at Booth 29 Sat, Nov 710:00am–4:00pm, 6:00–7:30pmSun, Nov 810:00am–4:00pmMon, Nov 98:30am–10:30am Talk Sat Nov 7 3:15pm–4:00pm Part of Poster Tour Signatera Genome™ Assay for Enhanced ctDNA Detection in a Cohort of Patients (pts) with Solid Tumors Industry Mon Nov 9 9:00am–10:00am MRD Testing: Liquid Biopsy Reimagined for Real-Time Disease Monitoring ctDNA & MRD Poster Part of Poster sessions Budget Impact of Circulating Tumor DNA-guided Decisions in Post-radical Cystectomy High-risk Muscle-invasive Bladder Cancer in the United Kingdom Pre-analytics · ctDNA & MRD
Actorius Porter Ranch, CA
actorius.com Diagnostics & testing labs Develops circulating tumor cell technologies, including the OncoDiscover CTC test and an extracorporeal system for capturing tumor cells from blood.	Booth Exhibiting at Booth 7 Sat, Nov 710:00am–4:00pm, 6:00–7:30pmSun, Nov 810:00am–4:00pmMon, Nov 98:30am–10:30am Talk Sat Nov 7 3:15pm–4:00pm Part of Poster Tour Detection of Androgen Receptor Splice Variant 7 in Circulating Tumor Cells for Dynamic Treatment Decision in Prostate Cancer Patients Poster Part of Poster sessions Evaluation of Circulating Tumor Cells Expressing PD-L1 and CTC Clusters at Baseline and Follow ups in Triple-negative Breast Cancer New analytes · Clinical use Collaborators: St. John's Medical College Hospital Poster Part of Poster sessions Algorithm Based Analysis of Circulating Tumour Cells in Cancer Patients New analytes · AI & data Poster Part of Poster sessions Capture of Cancerous Cells and Overall Survival in Rats using Ex-vivo Extracorporeal Device in Multiple Onco-dialysis Cycles New analytes Poster Part of Poster sessions Capture of Epithelial-mesenchymal Transitioning Circulating Tumor Cells using Affinity Based N-cadherin System New analytes Poster Part of Poster sessions Comparative Analysis of Circulating Tumor Cells, Clusters, and PD-L1 Expression in Paired Peripheral and Portal Venous Blood with Solid Malignancies New analytes · Pre-analytics Poster Part of Poster sessions Assessment of apprehension for Minimal Cellular Residual Disease Using Circulating Tumour Cells in Pre and Post Surgery Breast Cancer Patients New analytes · ctDNA & MRD
Guardant Health Palo Alto, CA	◆Gold Sponsor
guardanthealth.com Diagnostics & testing labsGold Sponsor Blood and tissue cancer tests for screening, recurrence monitoring and treatment selection, plus real-world data and analytics for drug developers.	Booth Exhibiting at Booth 2 Sat, Nov 710:00am–4:00pm, 6:00–7:30pmSun, Nov 810:00am–4:00pmMon, Nov 98:30am–10:30am Session Sat Nov 7 1:45pm–3:15pm Stakeholder Workshop Industry Mon Nov 9 8:00am–9:00am From Plasma to Practice: Longitudinal Insights for Breast and Lung Cancer Clinical use · ctDNA & MRD Poster Part of Poster sessions HLA and Pharmacogenomics Typing Concordance Between Buffy Coat Sequencing and a Plasma-based Liquid Biopsy Assay New analytes · Pre-analytics
1Cell.Ai Cupertino, CA
1cell.ai Diagnostics & testing labs Precision oncology testing company combining single-cell multi-omics of circulating tumor cells with AI, with a clinical laboratory in India.	Poster Part of Poster sessions Blood-derived HRD Assessment Enables Non-invasive Identification of Patients Eligible for DNA Repair-targeted Therapies Clinical use · ctDNA & MRD Poster Part of Poster sessions Liquid Biopsy Based Molecular Landscape Reveals Clinically Relevant Actionable Biomarkers in Small Cell Lung Cancer Clinical use
Flomics Biotech Barcelona, Spain
flomics.com Diagnostics & testing labs Develops a cell-free RNA blood test for early cancer detection using sequencing and machine learning, and offers RNA sequencing and bioinformatics services.	Poster Part of Poster sessions A Robust Cell-free RNA Approach for the Early Detection of Colorectal Cancer Early detection · New analytes Poster Part of Poster sessions Cell-free RNA in Precision Medicine: Unlocking New Clinical Insights with ARdeNA New analytes Collaborators: Hospital Sant Joan de Déu Barcelona, University of Valencia
TG Tvaster Genkalp Chennai, India
Diagnostics & testing labs Develops cfDNA methylation blood tests, led by Episcreen Liver for hepatocellular carcinoma screening and surveillance.	Talk Mon Nov 9 10:00am–11:30am Part of Preferred Oral Abstract Session Episcreen® Liver: Clinical Performance of a cfDNA Methylation Blood Test with AI Integration for Hepatocellular Carcinoma Screening, Surveillance and Treatment Response Poster Part of Poster sessions Detection of Chemotherapy Resistance and Recurrence in Paediatric Liver Tumors Using a cfDNA Hypermethylation Test: A Pilot Clinical Study ctDNA & MRD · Clinical use
OncoHost Binyamina, Israel	◇Bronze Sponsor
oncohost.com Diagnostics & testing labsBronze Sponsor Offers PROphet, a blood proteomics platform; its PROphetNSCLC test informs first-line immunotherapy decisions in non-small cell lung cancer.	Booth Exhibiting at Booth 8 Sat, Nov 710:00am–4:00pm, 6:00–7:30pmSun, Nov 810:00am–4:00pmMon, Nov 98:30am–10:30am Industry Sat Nov 7 11:50am–12:10pm Expanding Liquid Biopsy Through Plasma Proteomics: Immunotherapy Outcomes Across Molecular, Temporal, and Disease Contexts New analytes · Clinical use Session Sat Nov 7 1:45pm–3:15pm Stakeholder Workshop Talk Sat Nov 7 3:15pm–4:00pm Part of Poster Tour Longitudinal Plasma Proteomic Profiling Predicts Immunotherapy Response Dynamics and Overall Survival (OS) in NSCLC
Veracyte South San Francisco, CA	◇Bronze Sponsor
veracyte.com Diagnostics & testing labsBronze Sponsor Diagnostics company whose tests give clinicians insights to guide cancer diagnosis and treatment decisions.	Booth Exhibiting at Booth 17 Sat, Nov 710:00am–4:00pm, 6:00–7:30pmSun, Nov 810:00am–4:00pmMon, Nov 98:30am–10:30am Industry Mon Nov 9 9:00am–10:00am Whole-Genome Approaches to ctDNA-Based MRD Monitoring: Current Evidence and Future Opportunities ctDNA & MRD Industry Mon Nov 9 9:00am–10:00am Part of Whole-Genome Approaches to ctDNA-Based MRD Monitoring: Current Evidence and Future Opportunities Veracyte and TrueMRD Platform Overview ctDNA & MRD Industry Mon Nov 9 9:00am–10:00am Part of Whole-Genome Approaches to ctDNA-Based MRD Monitoring: Current Evidence and Future Opportunities Studies Pipeline and Closing ctDNA & MRD
SOPHiA GENETICS	◇Silver Sponsor
sophiagenetics.com Diagnostics & testing labsSilver Sponsor Cloud software company whose platform analyzes multimodal diagnostic data and lets healthcare institutions share knowledge for data-driven medicine.	Booth Exhibiting at Booth 28 Sat, Nov 710:00am–4:00pm, 6:00–7:30pmSun, Nov 810:00am–4:00pmMon, Nov 98:30am–10:30am Session Sat Nov 7 1:45pm–3:15pm Stakeholder Workshop Industry Mon Nov 9 11:30am–12:30pm Industry Afternoon Symposium: SOPHiA GENETICS
GenoME Diagnostics Belfast, United Kingdom
genomediagnostics.co.uk Diagnostics & testing labs Queen's University Belfast spinout developing blood tests that read DNA methylation and fragmentation, for ovarian cancer monitoring and pancreatic cancer detection.	Talk Sun Nov 8 3:00pm–3:45pm Part of Poster Tour Development of A Novel Digital PCR Multiplex Test for Improved Ovarian Cancer Disease Monitoring. Poster Part of Poster sessions Development of Novel Liquid Biopsy for the Improved Diagnosis of Pancreatic Cancers. Early detection
Caris Life Sciences Irving, TX
carislifesciences.com Diagnostics & testing labs Molecular profiling company testing tumor DNA, RNA and proteins, backed by a large molecular and clinical database and AI models.	Booth Exhibiting at Booth 5 Sat, Nov 710:00am–4:00pm, 6:00–7:30pmSun, Nov 810:00am–4:00pmMon, Nov 98:30am–10:30am Poster Part of Poster sessions Clinical Impact of Matched Plasma & WBC DNA Sequencing for Variant-origin Classification of PARP Inhibitor-associated Alterations in Prostate Cancer Clinical use · ctDNA & MRD Collaborators: University of Minnesota